NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aulos Bioscience

Aulos Bioscience

Private
Larkspur, CaliforniaHealthcare & Life Scienceshttps://aulosbio.com/

Last Round

Series A

Extension

Aug 1, 2023

Total Funding Raised

$60M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Aulos Bioscience is a biotechnology company that develops innovative immuno-oncology therapeutics and IL-2 targeting antibodies to direct patients' immune systems toward killing solid tumor cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

immuno-oncologymonoclonal antibodyIL-2interleukin-2solid tumorscheckpoint inhibitordrug discoveryAI drug discoverybiotechclinical-stage biotechmetastatic melanomanon-small cell lung cancerNSCLCcomputational biologyAI-first biotechtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aulos Bioscience Comparables

Compare Aulos Bioscience with similar companies based on industry and business-model similarity.

Aulos Bioscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synthekine
85%
Anaveon
84%
Anwita Biosciences Inc.
80%

Aulos Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionAug 1, 2023
Series AJan 8, 2021

Key People

Founding team and executive leadership

Micah Pearlman

Chief Operating Officer and Co-Founder

Founding Team

Aron Knickerbocker

Chief Executive Officer

Executive Team

Leo Redmond

Chief Financial Officer

Executive Team

Aulos Bioscience Investors

Notable investors and investment history

Aulos Bioscience investors
InvestorRounds
Apple Tree PartnersSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 174% MoM, reaching 6K.

  • Nov 12, 2025

    Developing a human monoclonal antibody targeting regulatory T cells.

Aulos Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aulos Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aulos Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersLarkspur, California
Employee Range15
Year Founded2020
Last FundingAug 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.